img

Global COVID-19 Recombinant Protein Vaccine Market Research Report 2024

Published on: 2024-01-04 | No of Pages : 400 | Industry : Latest Trends

Publisher : MRA | Format : PDF

Global COVID-19 Recombinant Protein Vaccine Market Research Report 2024

Preparation and immunogenicity and immunoprotection of Hib polysaccharide conjugate vaccine based on pneumococcal surface adhesive (PsaA).Methods PsaA gene recombinant protein (rPsaA) was prepared by genetic engineering, and then conjugated with Hib polysaccharide by amide condensation.The 3-week-old mice were immunized with this vaccine, and mice were inoculated with tetanus toxoid and haemophilus influenzae type B (Hib) polysaccharide conjugate vaccine (hib-tt) as controls and phosphate buffer (PBS) as blank controls.
According to MRA Research’s new survey, global COVID-19 Recombinant Protein Vaccine market is projected to reach US$ million in 2033, increasing from US$ million in 2023, with the CAGR of % during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole COVID-19 Recombinant Protein Vaccine market research.
Key companies engaged in the COVID-19 Recombinant Protein Vaccine industry include GSK, Johnson & Johnson, Sanofi, Novavax, Pukang Biologic Technology, Clover Biopharmaceuticals and Suzhou Yuzhibo Biotechnology, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2023.
When refers to consumption region, % value of COVID-19 Recombinant Protein Vaccine were sold to North America, Europe and Asia Pacific in 2023. Moreover, China, plays a key role in the whole COVID-19 Recombinant Protein Vaccine market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2023) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global COVID-19 Recombinant Protein Vaccine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.



By Company


GSK
Johnson & Johnson
Sanofi
Novavax
Pukang Biologic Technology
Clover Biopharmaceuticals
Suzhou Yuzhibo Biotechnology
Segment by Type
Being Developed
Preclinical
Clinical I
Clinical II

Segment by Application


Pharmaceutical And Biotechnology Companies
Hospital
Academic And Research Organizations
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The COVID-19 Recombinant Protein Vaccine report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global COVID-19 Recombinant Protein Vaccine Market Size Growth Rate by Type: 2018 VS 2023 VS 2033
1.2.2 Being Developed
1.2.3 Preclinical
1.2.4 Clinical I
1.2.5 Clinical II
1.3 Market by Application
1.3.1 Global COVID-19 Recombinant Protein Vaccine Market Growth by Application: 2018 VS 2023 VS 2033
1.3.2 Pharmaceutical And Biotechnology Companies
1.3.3 Hospital
1.3.4 Academic And Research Organizations
1.3.5 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global COVID-19 Recombinant Protein Vaccine Market Perspective (2018-2033)
2.2 COVID-19 Recombinant Protein Vaccine Growth Trends by Region
2.2.1 Global COVID-19 Recombinant Protein Vaccine Market Size by Region: 2018 VS 2023 VS 2033
2.2.2 COVID-19 Recombinant Protein Vaccine Historic Market Size by Region (2018-2023)
2.2.3 COVID-19 Recombinant Protein Vaccine Forecasted Market Size by Region (2024-2033)
2.3 COVID-19 Recombinant Protein Vaccine Market Dynamics
2.3.1 COVID-19 Recombinant Protein Vaccine Industry Trends
2.3.2 COVID-19 Recombinant Protein Vaccine Market Drivers
2.3.3 COVID-19 Recombinant Protein Vaccine Market Challenges
2.3.4 COVID-19 Recombinant Protein Vaccine Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top COVID-19 Recombinant Protein Vaccine Players by Revenue
3.1.1 Global Top COVID-19 Recombinant Protein Vaccine Players by Revenue (2018-2023)
3.1.2 Global COVID-19 Recombinant Protein Vaccine Revenue Market Share by Players (2018-2023)
3.2 Global COVID-19 Recombinant Protein Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by COVID-19 Recombinant Protein Vaccine Revenue
3.4 Global COVID-19 Recombinant Protein Vaccine Market Concentration Ratio
3.4.1 Global COVID-19 Recombinant Protein Vaccine Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by COVID-19 Recombinant Protein Vaccine Revenue in 2023
3.5 COVID-19 Recombinant Protein Vaccine Key Players Head office and Area Served
3.6 Key Players COVID-19 Recombinant Protein Vaccine Product Solution and Service
3.7 Date of Enter into COVID-19 Recombinant Protein Vaccine Market
3.8 Mergers & Acquisitions, Expansion Plans
4 COVID-19 Recombinant Protein Vaccine Breakdown Data by Type
4.1 Global COVID-19 Recombinant Protein Vaccine Historic Market Size by Type (2018-2023)
4.2 Global COVID-19 Recombinant Protein Vaccine Forecasted Market Size by Type (2024-2033)
5 COVID-19 Recombinant Protein Vaccine Breakdown Data by Application
5.1 Global COVID-19 Recombinant Protein Vaccine Historic Market Size by Application (2018-2023)
5.2 Global COVID-19 Recombinant Protein Vaccine Forecasted Market Size by Application (2024-2033)
6 North America
6.1 North America COVID-19 Recombinant Protein Vaccine Market Size (2018-2033)
6.2 North America COVID-19 Recombinant Protein Vaccine Market Growth Rate by Country: 2018 VS 2023 VS 2033
6.3 North America COVID-19 Recombinant Protein Vaccine Market Size by Country (2018-2023)
6.4 North America COVID-19 Recombinant Protein Vaccine Market Size by Country (2024-2033)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe COVID-19 Recombinant Protein Vaccine Market Size (2018-2033)
7.2 Europe COVID-19 Recombinant Protein Vaccine Market Growth Rate by Country: 2018 VS 2023 VS 2033
7.3 Europe COVID-19 Recombinant Protein Vaccine Market Size by Country (2018-2023)
7.4 Europe COVID-19 Recombinant Protein Vaccine Market Size by Country (2024-2033)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific COVID-19 Recombinant Protein Vaccine Market Size (2018-2033)
8.2 Asia-Pacific COVID-19 Recombinant Protein Vaccine Market Growth Rate by Region: 2018 VS 2023 VS 2033
8.3 Asia-Pacific COVID-19 Recombinant Protein Vaccine Market Size by Region (2018-2023)
8.4 Asia-Pacific COVID-19 Recombinant Protein Vaccine Market Size by Region (2024-2033)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America COVID-19 Recombinant Protein Vaccine Market Size (2018-2033)
9.2 Latin America COVID-19 Recombinant Protein Vaccine Market Growth Rate by Country: 2018 VS 2023 VS 2033
9.3 Latin America COVID-19 Recombinant Protein Vaccine Market Size by Country (2018-2023)
9.4 Latin America COVID-19 Recombinant Protein Vaccine Market Size by Country (2024-2033)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa COVID-19 Recombinant Protein Vaccine Market Size (2018-2033)
10.2 Middle East & Africa COVID-19 Recombinant Protein Vaccine Market Growth Rate by Country: 2018 VS 2023 VS 2033
10.3 Middle East & Africa COVID-19 Recombinant Protein Vaccine Market Size by Country (2018-2023)
10.4 Middle East & Africa COVID-19 Recombinant Protein Vaccine Market Size by Country (2024-2033)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 GSK
11.1.1 GSK Company Detail
11.1.2 GSK Business Overview
11.1.3 GSK COVID-19 Recombinant Protein Vaccine Introduction
11.1.4 GSK Revenue in COVID-19 Recombinant Protein Vaccine Business (2018-2023)
11.1.5 GSK Recent Development
11.2 Johnson & Johnson
11.2.1 Johnson & Johnson Company Detail
11.2.2 Johnson & Johnson Business Overview
11.2.3 Johnson & Johnson COVID-19 Recombinant Protein Vaccine Introduction
11.2.4 Johnson & Johnson Revenue in COVID-19 Recombinant Protein Vaccine Business (2018-2023)
11.2.5 Johnson & Johnson Recent Development
11.3 Sanofi
11.3.1 Sanofi Company Detail
11.3.2 Sanofi Business Overview
11.3.3 Sanofi COVID-19 Recombinant Protein Vaccine Introduction
11.3.4 Sanofi Revenue in COVID-19 Recombinant Protein Vaccine Business (2018-2023)
11.3.5 Sanofi Recent Development
11.4 Novavax
11.4.1 Novavax Company Detail
11.4.2 Novavax Business Overview
11.4.3 Novavax COVID-19 Recombinant Protein Vaccine Introduction
11.4.4 Novavax Revenue in COVID-19 Recombinant Protein Vaccine Business (2018-2023)
11.4.5 Novavax Recent Development
11.5 Pukang Biologic Technology
11.5.1 Pukang Biologic Technology Company Detail
11.5.2 Pukang Biologic Technology Business Overview
11.5.3 Pukang Biologic Technology COVID-19 Recombinant Protein Vaccine Introduction
11.5.4 Pukang Biologic Technology Revenue in COVID-19 Recombinant Protein Vaccine Business (2018-2023)
11.5.5 Pukang Biologic Technology Recent Development
11.6 Clover Biopharmaceuticals
11.6.1 Clover Biopharmaceuticals Company Detail
11.6.2 Clover Biopharmaceuticals Business Overview
11.6.3 Clover Biopharmaceuticals COVID-19 Recombinant Protein Vaccine Introduction
11.6.4 Clover Biopharmaceuticals Revenue in COVID-19 Recombinant Protein Vaccine Business (2018-2023)
11.6.5 Clover Biopharmaceuticals Recent Development
11.7 Suzhou Yuzhibo Biotechnology
11.7.1 Suzhou Yuzhibo Biotechnology Company Detail
11.7.2 Suzhou Yuzhibo Biotechnology Business Overview
11.7.3 Suzhou Yuzhibo Biotechnology COVID-19 Recombinant Protein Vaccine Introduction
11.7.4 Suzhou Yuzhibo Biotechnology Revenue in COVID-19 Recombinant Protein Vaccine Business (2018-2023)
11.7.5 Suzhou Yuzhibo Biotechnology Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global COVID-19 Recombinant Protein Vaccine Market Size Growth Rate by Type (US$ Million): 2018 VS 2023 VS 2033
Table 2. Key Players of Being Developed
Table 3. Key Players of Preclinical
Table 4. Key Players of Clinical I
Table 5. Key Players of Clinical II
Table 6. Global COVID-19 Recombinant Protein Vaccine Market Size Growth by Application (US$ Million): 2018 VS 2023 VS 2033
Table 7. Global COVID-19 Recombinant Protein Vaccine Market Size by Region (US$ Million): 2018 VS 2023 VS 2033
Table 8. Global COVID-19 Recombinant Protein Vaccine Market Size by Region (2018-2023) & (US$ Million)
Table 9. Global COVID-19 Recombinant Protein Vaccine Market Share by Region (2018-2023)
Table 10. Global COVID-19 Recombinant Protein Vaccine Forecasted Market Size by Region (2024-2033) & (US$ Million)
Table 11. Global COVID-19 Recombinant Protein Vaccine Market Share by Region (2024-2033)
Table 12. COVID-19 Recombinant Protein Vaccine Market Trends
Table 13. COVID-19 Recombinant Protein Vaccine Market Drivers
Table 14. COVID-19 Recombinant Protein Vaccine Market Challenges
Table 15. COVID-19 Recombinant Protein Vaccine Market Restraints
Table 16. Global COVID-19 Recombinant Protein Vaccine Revenue by Players (2018-2023) & (US$ Million)
Table 17. Global COVID-19 Recombinant Protein Vaccine Market Share by Players (2018-2023)
Table 18. Global Top COVID-19 Recombinant Protein Vaccine Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in COVID-19 Recombinant Protein Vaccine as of 2023)
Table 19. Ranking of Global Top COVID-19 Recombinant Protein Vaccine Companies by Revenue (US$ Million) in 2023
Table 20. Global 5 Largest Players Market Share by COVID-19 Recombinant Protein Vaccine Revenue (CR5 and HHI) & (2018-2023)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players COVID-19 Recombinant Protein Vaccine Product Solution and Service
Table 23. Date of Enter into COVID-19 Recombinant Protein Vaccine Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global COVID-19 Recombinant Protein Vaccine Market Size by Type (2018-2023) & (US$ Million)
Table 26. Global COVID-19 Recombinant Protein Vaccine Revenue Market Share by Type (2018-2023)
Table 27. Global COVID-19 Recombinant Protein Vaccine Forecasted Market Size by Type (2024-2033) & (US$ Million)
Table 28. Global COVID-19 Recombinant Protein Vaccine Revenue Market Share by Type (2024-2033)
Table 29. Global COVID-19 Recombinant Protein Vaccine Market Size by Application (2018-2023) & (US$ Million)
Table 30. Global COVID-19 Recombinant Protein Vaccine Revenue Market Share by Application (2018-2023)
Table 31. Global COVID-19 Recombinant Protein Vaccine Forecasted Market Size by Application (2024-2033) & (US$ Million)
Table 32. Global COVID-19 Recombinant Protein Vaccine Revenue Market Share by Application (2024-2033)
Table 33. North America COVID-19 Recombinant Protein Vaccine Market Size Growth Rate by Country (US$ Million): 2018 VS 2023 VS 2033
Table 34. North America COVID-19 Recombinant Protein Vaccine Market Size by Country (2018-2023) & (US$ Million)
Table 35. North America COVID-19 Recombinant Protein Vaccine Market Size by Country (2024-2033) & (US$ Million)
Table 36. Europe COVID-19 Recombinant Protein Vaccine Market Size Growth Rate by Country (US$ Million): 2018 VS 2023 VS 2033
Table 37. Europe COVID-19 Recombinant Protein Vaccine Market Size by Country (2018-2023) & (US$ Million)
Table 38. Europe COVID-19 Recombinant Protein Vaccine Market Size by Country (2024-2033) & (US$ Million)
Table 39. Asia-Pacific COVID-19 Recombinant Protein Vaccine Market Size Growth Rate by Region (US$ Million): 2018 VS 2023 VS 2033
Table 40. Asia-Pacific COVID-19 Recombinant Protein Vaccine Market Size by Region (2018-2023) & (US$ Million)
Table 41. Asia-Pacific COVID-19 Recombinant Protein Vaccine Market Size by Region (2024-2033) & (US$ Million)
Table 42. Latin America COVID-19 Recombinant Protein Vaccine Market Size Growth Rate by Country (US$ Million): 2018 VS 2023 VS 2033
Table 43. Latin America COVID-19 Recombinant Protein Vaccine Market Size by Country (2018-2023) & (US$ Million)
Table 44. Latin America COVID-19 Recombinant Protein Vaccine Market Size by Country (2024-2033) & (US$ Million)
Table 45. Middle East & Africa COVID-19 Recombinant Protein Vaccine Market Size Growth Rate by Country (US$ Million): 2018 VS 2023 VS 2033
Table 46. Middle East & Africa COVID-19 Recombinant Protein Vaccine Market Size by Country (2018-2023) & (US$ Million)
Table 47. Middle East & Africa COVID-19 Recombinant Protein Vaccine Market Size by Country (2024-2033) & (US$ Million)
Table 48. GSK Company Detail
Table 49. GSK Business Overview
Table 50. GSK COVID-19 Recombinant Protein Vaccine Product
Table 51. GSK Revenue in COVID-19 Recombinant Protein Vaccine Business (2018-2023) & (US$ Million)
Table 52. GSK Recent Development
Table 53. Johnson & Johnson Company Detail
Table 54. Johnson & Johnson Business Overview
Table 55. Johnson & Johnson COVID-19 Recombinant Protein Vaccine Product
Table 56. Johnson & Johnson Revenue in COVID-19 Recombinant Protein Vaccine Business (2018-2023) & (US$ Million)
Table 57. Johnson & Johnson Recent Development
Table 58. Sanofi Company Detail
Table 59. Sanofi Business Overview
Table 60. Sanofi COVID-19 Recombinant Protein Vaccine Product
Table 61. Sanofi Revenue in COVID-19 Recombinant Protein Vaccine Business (2018-2023) & (US$ Million)
Table 62. Sanofi Recent Development
Table 63. Novavax Company Detail
Table 64. Novavax Business Overview
Table 65. Novavax COVID-19 Recombinant Protein Vaccine Product
Table 66. Novavax Revenue in COVID-19 Recombinant Protein Vaccine Business (2018-2023) & (US$ Million)
Table 67. Novavax Recent Development
Table 68. Pukang Biologic Technology Company Detail
Table 69. Pukang Biologic Technology Business Overview
Table 70. Pukang Biologic Technology COVID-19 Recombinant Protein Vaccine Product
Table 71. Pukang Biologic Technology Revenue in COVID-19 Recombinant Protein Vaccine Business (2018-2023) & (US$ Million)
Table 72. Pukang Biologic Technology Recent Development
Table 73. Clover Biopharmaceuticals Company Detail
Table 74. Clover Biopharmaceuticals Business Overview
Table 75. Clover Biopharmaceuticals COVID-19 Recombinant Protein Vaccine Product
Table 76. Clover Biopharmaceuticals Revenue in COVID-19 Recombinant Protein Vaccine Business (2018-2023) & (US$ Million)
Table 77. Clover Biopharmaceuticals Recent Development
Table 78. Suzhou Yuzhibo Biotechnology Company Detail
Table 79. Suzhou Yuzhibo Biotechnology Business Overview
Table 80. Suzhou Yuzhibo Biotechnology COVID-19 Recombinant Protein Vaccine Product
Table 81. Suzhou Yuzhibo Biotechnology Revenue in COVID-19 Recombinant Protein Vaccine Business (2018-2023) & (US$ Million)
Table 82. Suzhou Yuzhibo Biotechnology Recent Development
Table 83. Research Programs/Design for This Report
Table 84. Key Data Information from Secondary Sources
Table 85. Key Data Information from Primary Sources
List of Figures
Figure 1. Global COVID-19 Recombinant Protein Vaccine Market Size Comparison by Type (2023-2033) & (US$ Million)
Figure 2. Global COVID-19 Recombinant Protein Vaccine Market Share by Type: 2023 VS 2033
Figure 3. Being Developed Features
Figure 4. Preclinical Features
Figure 5. Clinical I Features
Figure 6. Clinical II Features
Figure 7. Global COVID-19 Recombinant Protein Vaccine Market Size Comparison by Application (2023-2033) & (US$ Million)
Figure 8. Global COVID-19 Recombinant Protein Vaccine Market Share by Application: 2023 VS 2033
Figure 9. Pharmaceutical And Biotechnology Companies Case Studies
Figure 10. Hospital Case Studies
Figure 11. Academic And Research Organizations Case Studies
Figure 12. Other Case Studies
Figure 13. COVID-19 Recombinant Protein Vaccine Report Years Considered
Figure 14. Global COVID-19 Recombinant Protein Vaccine Market Size (US$ Million), Year-over-Year: 2018-2033
Figure 15. Global COVID-19 Recombinant Protein Vaccine Market Size, (US$ Million), 2018 VS 2023 VS 2033
Figure 16. Global COVID-19 Recombinant Protein Vaccine Market Share by Region: 2023 VS 2033
Figure 17. Global COVID-19 Recombinant Protein Vaccine Market Share by Players in 2023
Figure 18. Global Top COVID-19 Recombinant Protein Vaccine Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in COVID-19 Recombinant Protein Vaccine as of 2023)
Figure 19. The Top 10 and 5 Players Market Share by COVID-19 Recombinant Protein Vaccine Revenue in 2023
Figure 20. North America COVID-19 Recombinant Protein Vaccine Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 21. North America COVID-19 Recombinant Protein Vaccine Market Share by Country (2018-2033)
Figure 22. United States COVID-19 Recombinant Protein Vaccine Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 23. Canada COVID-19 Recombinant Protein Vaccine Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 24. Europe COVID-19 Recombinant Protein Vaccine Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 25. Europe COVID-19 Recombinant Protein Vaccine Market Share by Country (2018-2033)
Figure 26. Germany COVID-19 Recombinant Protein Vaccine Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 27. France COVID-19 Recombinant Protein Vaccine Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 28. U.K. COVID-19 Recombinant Protein Vaccine Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 29. Italy COVID-19 Recombinant Protein Vaccine Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 30. Russia COVID-19 Recombinant Protein Vaccine Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 31. Nordic Countries COVID-19 Recombinant Protein Vaccine Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 32. Asia-Pacific COVID-19 Recombinant Protein Vaccine Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 33. Asia-Pacific COVID-19 Recombinant Protein Vaccine Market Share by Region (2018-2033)
Figure 34. China COVID-19 Recombinant Protein Vaccine Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 35. Japan COVID-19 Recombinant Protein Vaccine Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 36. South Korea COVID-19 Recombinant Protein Vaccine Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 37. Southeast Asia COVID-19 Recombinant Protein Vaccine Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 38. India COVID-19 Recombinant Protein Vaccine Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 39. Australia COVID-19 Recombinant Protein Vaccine Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 40. Latin America COVID-19 Recombinant Protein Vaccine Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 41. Latin America COVID-19 Recombinant Protein Vaccine Market Share by Country (2018-2033)
Figure 42. Mexico COVID-19 Recombinant Protein Vaccine Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 43. Brazil COVID-19 Recombinant Protein Vaccine Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 44. Middle East & Africa COVID-19 Recombinant Protein Vaccine Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 45. Middle East & Africa COVID-19 Recombinant Protein Vaccine Market Share by Country (2018-2033)
Figure 46. Turkey COVID-19 Recombinant Protein Vaccine Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 47. Saudi Arabia COVID-19 Recombinant Protein Vaccine Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 48. GSK Revenue Growth Rate in COVID-19 Recombinant Protein Vaccine Business (2018-2023)
Figure 49. Johnson & Johnson Revenue Growth Rate in COVID-19 Recombinant Protein Vaccine Business (2018-2023)
Figure 50. Sanofi Revenue Growth Rate in COVID-19 Recombinant Protein Vaccine Business (2018-2023)
Figure 51. Novavax Revenue Growth Rate in COVID-19 Recombinant Protein Vaccine Business (2018-2023)
Figure 52. Pukang Biologic Technology Revenue Growth Rate in COVID-19 Recombinant Protein Vaccine Business (2018-2023)
Figure 53. Clover Biopharmaceuticals Revenue Growth Rate in COVID-19 Recombinant Protein Vaccine Business (2018-2023)
Figure 54. Suzhou Yuzhibo Biotechnology Revenue Growth Rate in COVID-19 Recombinant Protein Vaccine Business (2018-2023)
Figure 55. Bottom-up and Top-down Approaches for This Report
Figure 56. Data Triangulation
Figure 57. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries